adenosine-5'-N-ehtylcarboxamide; piperazide-1-sulfonyl)phenyl]]-1-propylxanthine; SOD; superoxide dismutase; rm TNF-, recombinant mouse tumor necrosis factor-; WT, wild-type; XAC, xanthine amine congener.
INTRODUCTION
Adenosine is a purine nucleoside generated in response to ischemia and inflammation, partly by the extracellular catalysis by ecto-nucleotidases of ATP and ADP secreted by activated or injured cells (Hasko et al., 2008) . During acute inflammation, adenosine functions in a autocrine/paracrine manner to suppress activity of essentially all cells of the immune system, including the neutrophil, thereby dampening and resolving the inflammatory reaction (Cronstein, 1994; Hasko et al., 2008) . Among other actions, adenosine inhibits the superoxide burst produced by the NADPH complex in response to activating agents including host-and bacterial-derived formylated peptides, a process that is essential for killing phagocytosed bacteria but also promotes oxidant-induced tissue injury in inflammatory diseases such as asthma, arthritis, inflammatory bowel disease, and ischemia/reperfusion injury (Cronstein, 1994; Hasko et al., 2008) .
Among the four adenosine receptor (AR) subtypes (A 1 , A 2A , A 2B , and A 3 ; (Fredholm et al., 2000) , most previous studies have implicated the G s proteincoupled A 2A AR in mediating the suppressive actions of adenosine on stimulated superoxide production (Sullivan et al., 2001; Hasko et al., 2008) . However, it has become apparent in recent years that additional AR subtypes likely participate in this action. For example, it is now well established that the A 3 AR is abundantly expressed in neutrophils, surprisingly at a level that exceeds that of the A 2A AR This article has not been copyedited and formatted. The final version may differ from this version.
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Data from our laboratory recently demonstrated that the A 3 AR signals along with the A 2A AR to suppress the superoxide burst in murine neutrophils by a mechanism that appears to involve inhibition of the small GTPase Rac (van der Hoeven et al., 2008; van der Hoeven et al., 2010) .
In our previous studies (van der Hoeven et al., 2008; van der Hoeven et al., 2010) , we had also detected mRNA expression of the A 2B AR subtype at low levels in murine neutrophils that increased 15-fold during systemic inflammation (van der Hoeven et al., 2008) . Considering that the A 2B AR is a G s proteincoupled receptor like the A 2A AR (Feoktistov and Biaggioni, 1997; Fredholm et al., 2000) , in this investigation we tested the hypothesis that the A 2B AR couples to inhibition of stimulated superoxide production in neutrophils. We also examined whether the A 2B AR regulates neutrophil chemotaxis using a Boyden chamber migration assay (van der Hoeven et al., 2008) . Our studies involved the use of the A 2B AR agonist BAY 60-6385 (Beukers et al., 2004; Eckle et al., 2007) and A 2B AR gene knockout/β-galactosidase reporter gene knock-in (A 2B KO) mice (Auchampach et al., 1997; Kreckler et al., 2006) . The full-length cDNA sequences were obtained by RT-PCR using total RNA isolated from mouse brain (Kreckler et al., 2006) . The cDNAs were subcloned intol pCDNA3.1, transfected into HEK 293 cells using Lipofectamine, and selected with 2 mg/ml G418. In binding assays, crude membranes prepared from HEK 293 cells expressing mouse ARs (Kreckler et al., 2006) were incubated with various concentrations of radioligand and competitors in 100 μl of binding buffer (20 mM HEPES, 1 mM EDTA, 5 mM MgCl 2 , 1 unit/ml adenosine deaminase). After incubating at 25 o C for 3 h, bound and free radioligand were separated by rapid filtration over glass fiber filters. Non-specific binding was measured in the presence of 100 μM adenosine-5'-N-ethylcarboxamide (NECA). [ (agonist) was used with mouse A 2A ARs (Luthin et al., 1995; Murphree et al., 2002) . The radioligands were prepared by the chloramine-T method and purified by HPLC (Luthin et al., 1995; Auchampach et al., 1997; Murphree et al., 2002) .
In saturation binding assays, B max and K d values were obtained by fitting specific binding data to either single-or two-site binding models using non-linear least squares interpolation. An F-test was used to identify the model that provided the best fit. In competition assays with compounds binding to a single site, specific binding data was fit to: binding = non-specific binding + (total binding -specific ). K i values were calculated from IC 50 values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . In competition assays with compounds competing for two binding sites, two K i values for competitors were calculated by solving the following four equations simultaneously (Auchampach et al., 1997) :
where LB is radioligand bound, CB is competitor bound, L is free radiolgiand, C is free competitor, and f is fraction of L or C nonspecifically bound (assumed to be equal). K d1(high) and K d2(low) were obtained from equilibrium saturation binding experiments in the absence of competitor. The other values were determined by simultaneously solving the four equations by interpolation within each iteration of non-linear least-squares analysis (Auchampach et al., 1997) . ). The A 2B AR antagonists CVT-6883 (300 nM) and PSB 603 (300 nM)
were included in assays with cells expressing the A 1 , A 2A , or A 3 AR to inhibit A 2B ARs expressed endogenously in HEK 293 cells (Gao et al., 1999) . Activation of the A 2B AR inhibits fMLP-induced superoxide production by murine neutrophils. Treating neutrophils with BAY 60-6583 produced a biphasic effect on fMLP-stimulated superoxide production ( Figure 3A) . At low concentrations (1-10 nM), BAY 60-6583 reduced fMLP-stimulated superoxide production with a maximal inhibitory effect of ~50% at 10 nM. At higher concentrations (1-10 μM), however, BAY 60-6583 stimulated fMLP-induced superoxide production, producing a >50% increase over vehicle-treated cells at a concentration of 10 μM. In the absence of fMLP, treating neutrophils with BAY 60-6583 did not directly stimulate superoxide production (i.e., in the absence of fMLP) at any of the concentrations tested ( Figure 3B ). BAY 60-6583 (10 -11 -10 -5 ) also did not directly scavenge superoxide anions or interfere with light production by MCLA as determined in a cell-free superoxide-generating system composed of xanthine/xanthine oxidase (data not shown).
Isolation of Mouse
In assays using neutrophils isolated from A 2B KO mice, the inhibitory effect of BAY 60-6583 on fMLP-induced superoxide generation observed at low nanomolar concentrations was no longer evident, although it continued to potentiate superoxide production at higher concentrations ( Figure 4A) . A similar profile with BAY 60-6583 was observed with wild-type neutrophils in the presence of the non-selective AR antagonist xanthine amine congener (XAC 1 μM; Figure 4B ).
These results indicate that the inhibitory effect of BAY 60-6583 on fMLPstimulated superoxide production at lower concentrations was mediated via the A 2B AR, whereas the stimulatory effect at higher concentrations was due to a nonspecific, AR-independent mechanism.
BAY 60-6583 also produced a bi-phasic response on fMLP-induced superoxide production in assays using TNF-α-primed neutrophils (100 ng/ml for 30 min) or 
DISCUSSION
We previously identified expression of the low affinity A 2B AR subtype in murine neutrophils that is transcriptionally induced during systemic inflammation (van der Hoeven et al., 2008) . In this study, we demonstrated that the A 2B AR signals in murine neutrophils to inhibit superoxide production, but does not appear to modulate chemotaxis. Our results indicate that the A 2B AR participates in mediating the inhibitory actions of adenosine on neutrophils. Considering that the A 2B AR is a low-affinity receptor for adenosine and that its expression is induced in response to hypoxia or inflammatory stimuli (Eckle et al., 2007; der Hoeven et al., 2008; Hasko et al., 2009) , we propose that A 2B AR signaling may become increasingly important during inflammation resolution and when adenosine levels in tissues are high.
Based on the results of this investigation and previous work from our group and others, it is now apparent that three different AR subtypes expressed in murine neutrophils (A 2A , A 2B and A 3 ) are capable of regulating stimulated superoxide production (Cronstein et al., 1985; Cronstein et al., 1992; Cronstein, 1994; Fredholm et al., 1996; Sullivan et al., 2001; van der Hoeven et al., 2008; van der Hoeven et al., 2010) Neutrophil oxidant production is catalyzed by the multi-component NADPH oxidase complex composed of cytosolic subunits (p47phox, p67phox, p40phox, and Rac2) that migrate to the membrane and associate with membrane subunits (p22phox and gp91phox) upon activation (Groemping and Rittinger, 2005) . The complex catalyzes NADPH-dependent reduction of oxygen to superoxide anion (Groemping and Rittinger, 2005) . The extent of neutrophil superoxide production is enhanced anywhere from ~4-15-fold following exposure to TNF-α and a variety of other pro-inflammatory cytokines, a process that is termed neutrophil "priming (Dewas et al., 2003; Boussetta et al., 2010) . The mechanism of priming by TNF-α is not completely understood, but appears to involve hyper-phosphorylation of the cytosolic p47phox subunit of the NADPH complex that may be facilitated following isomerization of a phosphorylated serine residue within the carboxyl terminal region of the protein (Dewas et al., 2003; Boussetta et al., 2010) .
Priming serves to amplify the destructive actions of neutrophils selectively within regions that are inflamed. Our data indicates that activation of the A 2B AR is able to continue to suppress fMLP-stimulated superoxide by neutrophils that had been , 2008) . In this experiment, the efficacy of BAY 60-6583 was reduced even though expression of the A 2B AR was induced. At a molecular level, the reduced efficacy with TNF-α priming may be related to previous reports that AR activation does not inhibit neutrophil superoxide production in response to phorbol esters that directly activate protein kinase C, and that the molecular mechanism of TNF-α-priming involving p47phox hyper-phosphorylation is protein kinase Cdependent (Cronstein et al., 1985; van der Hoeven et al., 2008; Boussetta et al., 2010) . It is notable that in our previous studies of murine neutrophils we also observed that the extent of inhibition of stimulated superoxide production provided by A 2A and A 3 AR activation was similarly reduced following priming by TNF-α (van der Hoeven et al., 2008) .
BAY 60-6583 is member of a new series of 6-amino-3,5-dicyano-4-phenylpyridine derivatives that has recently been identified as selective agonist for the human A 2B AR (Beukers et al., 2004; Eckle et al., 2007) . In preliminary studies, we carefully examined the binding affinity and functional potency of BAY 60-6583 for murine ARs. Comparisons were made with the adenosine analog NECA, which has been used extensively as a pharmacological agonist for the Table 1 and the cAMP data in Figure 1 is that BAY 60-6583 binds to the mouse A 1 AR with a K i value of 232 nM (Table 1) when expressed in HEK 293 cells, as described previously by our laboratory (Auchampach et al., 2009 ).
We did not explore the signaling mechanisms by which the A 2B AR inhibits superoxide production. Considering that the A 2B AR is coupled to G s proteins, it is likely that it functions similarly to the A 2A AR, namely through either elevation of cAMP (Sullivan et al., 2001) or G s protein-mediated uncoupling of chemoattractant receptors (Cronstein et al., 1992) . The A 2B AR differs from the A 2A AR, however, in being capable of dually coupling to both G s and G q proteins in some cells types (Feoktistov and Biaggioni, 1997; Fredholm et al., 2000) .
Thus, the participation of additional or alternative signaling mechanisms remains possible.
Our evidence for involvement of the A 2B AR is based on the observation that BAY 60-6583 inhibited fMLP-stimulated superoxide generation at low concentrations that correlated with its potency at activating the murine A 2B AR. At concentrations between 1 and 10 nM, BAY 60-6583 inhibited fMLP-stimulated superoxide production of naïve cells as well as neutrophils primed with TNF-α or systemic exposure to LPS. This potent effect of BAY 60-6583 was not apparent in studies using neutrophils isolated from A 2B KO mice. Interestingly, however, the effect of Cronstein et al., 1990; Chen et al., 2006; Zhang et al., 2006; van der Hoeven et al., 2008) . To address the possible involvement of the A 2B AR, we examined the effect of BAY 60-6583 on chemotaxis of murine neutrophils in a standard Boyden chamber assay, and found that it had no effect to directly stimulate chemotaxis or to modulate chemotactic activity produced by fMLP. While these data provide evidence that the A 2B AR likely does not participate in chemotaxis of murine neutrophils, it will be important to investigate this issue further using dynamic assays that can accurately detect effects on direction sensing and migration velocity (Chen et al., 2006) .
The results of this investigation demonstrate that selective activation of the A 2B AR in murine neutrophils inhibits fMLP-stimulated superoxide production.
This observation supports the concept that the A 2B AR likely participates along with other AR subtypes in transducing some of the inhibitory actions of adenosine on neutrophils. Recent studies using A 2B This article has not been copyedited and formatted. The final version may differ from this version. have provided evidence that the A 2B AR plays a protective role in various models of acute tissue injury in the heart, lungs, kidneys, gastrointestinal tract, and blood vessels Schingnitz et al.; Zhou et al.; Eckle et al., 2007; Eckle et al., 2008a; Eckle et al., 2008b; Grenz et al., 2008; Yang et al., 2008; Chen et al., 2009; Eltzschig et al., 2009; Hart et al., 2009) . It has been proposed that the protective action of the A 2B AR in these models may involve anti-inflammation related to reduced pro-inflammatory cytokine expression, inhibition of platelet aggregation, and promotion of barrier function within the vasculature and alveoli Schingnitz et al.; Zhou et al.; Eckle et al., 2007; Eckle et al., 2008a; Eckle et al., 2008b; Grenz et al., 2008; Yang et al., 2008; Chen et al., 2009; Eltzschig et al., 2009; Hart et al., 2009) . The data reported herein provide evidence that an additional contributing mechanism may involve suppression of oxidant injury by neutrophils.
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